Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05921929 Withdrawn - Clinical trials for Major Depressive Disorder

First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

Start date: May 2, 2024
Phase: Phase 1
Study type: Interventional

The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: - What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)? - What is the PK profile of single ascending doses of the FENM in human? - What is the preliminary exploratory time course of Brain Disease Neurotrophic Factor (BDNF) plasmatic levels of single ascending doses of the FENM? Participants will receive one single oral dose of FENM.

NCT ID: NCT05724849 Withdrawn - Depression Clinical Trials

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a pilot double-blinded, randomized, placebo-controlled trial to determine if venlafaxine prevents depression in patients undergoing surgery for Head and Neck Cancer (HNC).

NCT ID: NCT05693792 Withdrawn - Clinical trials for Postpartum Depression

A Six-Month Prospective Follow-Up Study of WB001

Start date: February 1, 2023
Phase:
Study type: Observational

This study is a 6-month follow-up study to WB001-001 conducted to assess and evaluate the durability of the effect of {WB001+TAU} beyond the 8-week treatment period.

NCT ID: NCT05615662 Withdrawn - Depression Clinical Trials

Meru Health Program to Treat Depression in Primary Care

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Meru Health Inc. seeks to further validate the Meru Health Program (MHP) as a single solution to screening, referral, and treatment in primary care as compared to treatment as usual using a Randomized Controlled Trial (RCT) study design. The goal of this study is to determine the feasibility, effectiveness, and implementability of this digital mental health (DMH) solution. If proven effective and implementable, more widely integrating the MHP into primary care has the potential to improve the systems of screening, referral, and treatment for depression nationwide. This, in turn, will serve as a solution to improve access to effective care for the millions of Americans currently suffering from depression, ultimately reducing its public health burden.

NCT ID: NCT05601648 Withdrawn - Clinical trials for Major Depressive Disorder

PET Synaptogenesis After Psilocybin In DEpression Recovery

PET-SPIDER
Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

Participants with depression will be given a single dose of psilocybin and supportive psychotherapy before, during, and after drug administration. Participants will undergo positron emission tomography (PET) imaging before and one week after psilocybin using a marker of synaptic density. This design allows us to assess the relationship between neurotrophic, and antidepressant effects produced by psilocybin.

NCT ID: NCT05594667 Withdrawn - Depression Clinical Trials

Effect of SSRIs on Response to Psilocybin Therapy

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups: - Group 1: ≤ 1 year - Group 2: 1 to ≤ 5 years - Group 3: 5 to ≤ 10 years - Group 4: > 10 years

NCT ID: NCT05554627 Withdrawn - Clinical trials for Depressive Disorder, Major

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

VAST-D II
Start date: October 27, 2023
Phase: Phase 4
Study type: Interventional

This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs. adjunctive aripiprazole (ARI) in Veterans with unipolar Treatment Resistant Depression (TRD). This study will assess the efficacy, safety, and acceptability of adjunctive IN ESK in comparison to ARI, one of the best studied and most widely used adjunctive therapies for TRD. The primary hypothesis is that participants receiving adjunctive IN ESK will be significantly more likely to achieve remission after six weeks of treatment as compared to those who receive adjunctive ARI. Depressive symptoms will be assessed by central raters (CR), blinded to treatment assignment, using the clinician rated version of the Quick Inventory of Depressive Symptomatology (QIDS-C16), a well-validated tool that is commonly used and is easily translated across other depression inventory scales. The study is powered to detect an absolute difference in remission rates of 10%, or larger, at 6 weeks. Additional outcomes of interest include symptom reduction across 6 months of randomized therapy, side effects and other tolerability indices, attrition rates and measures of quality of life and cost-effectiveness.

NCT ID: NCT05504486 Withdrawn - Clinical trials for Major Depressive Disorder (MDD)

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Start date: August 29, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

NCT ID: NCT05482672 Withdrawn - Depression Clinical Trials

GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression

Start date: April 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators have previously identified knee osteoarthritis patients with the combination of depression and an unhealthy weight may be an increased risk of more rapid joint degeneration and worsening pain. The GetHealthy-OA program combines a mind-body program with the oral supplement fisetin to potentially reduce the risk for this population by treating psychosocial, mechanical, and inflammatory mechanisms of knee osteoarthritis. This randomized clinical trial will compare the GetHealthy-OA program to minimally-enhanced usual care plus an oral placebo.

NCT ID: NCT05438758 Withdrawn - Clinical trials for Treatment Resistant Major Depressive Disorder

Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study

ZYL-730-02
Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)